Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017

A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report published in the Journal of Clinical Investigation, the team based in the Edwin L. Steele Laboratories for Tumor Biology in the MGH Department of Radiation Oncology describes finding in mouse models how anti-angiogenesis treatment induces a microenvironment that suppresses immune systems actions that would otherwise help to eliminate a tumor. They also developed a potential strategy for getting around this resistance mechanism.

"Deciphering and targeting mechanisms involved in to anti-angiogenic therapy is critical to realizing the full potential of this promising cancer therapy," says Dai Fukumura, MD, PhD, deputy director of the Steele Labs, co-senior author of the paper. "Not only is this the first report investigating the role in anti-angiogenic cancer therapy of a subset of innate immune cells - Ly6Clow or non-classical monocytes - it is also the first to find an immunosuppressive function for these cells and to identify that as the key mechanism conferring resistance to anti-angiogenic therapy."

Angiogenesis inhibitors - often given in combination with traditional therapies - can improve treatment for several types of cancer, both by restricting the growth of new blood vessels and by "normalizing" the abnormal vessels in and around a that can interfere with both chemotherapy and radiation therapy. But resistance to anti-angiogenic therapy limits the drugs' survival benefits. Several studies have suggested a role in the development of resistance for the immune system - particularly innate immune cells that suppress immune activity. But how specific subsets of these cells contribute to resistance has not been defined.

A series of experiments in mouse models of colorectal cancer first revealed that treatments blocking the vascular endothelial growth factor (VEGF) pathway - the target of approved anti-angiogenic drugs - induce the accumulation of monocytes and neutrophils. It soon became apparent that the buildup of non-classical monocytes - a subset previously identified as patrolling healthy blood vessels and possibly having an anti-tumor effect in lung cancer - was responsible for development of an immunosuppressive tumor microenvironment in colorectal cancer.

The research team identified the signaling pathway by which VEGF blockade induces expression of a molecule called CX3CL1 on tumor cells, attracting non-classical monocytes that carry the matching receptor. Those cells, in turn, attract neutrophils with another molecule called CXCL5; and both immune cells express factors that inhibit the proliferation of T cells, reducing the overall immune response to the tumor. Examination of biopsy samples taken from human patients before and after anti-angiogenic therapy revealed that expression of these chemokines - molecules that attract immune - increased in response to anti-VEGF treatment.

Since several methods of experimentally blocking the pathway improved the effects of anti-VEGF therapy in the mouse models, the team collaborated with Massachusetts Institute of Technology investigators to develop a potential gene therapy approach. Utilizing nanoparticle-delivered RNA interference against the interaction between CX3CL1 and its receptor, the approach significantly reduced the infiltration of non-classical monocytes into treated tumors and increased the beneficial effects of anti-VEGF therapy in a .

"Targeting resistance mechanisms can improve the efficacy of anti-angiogenic therapy drugs and help fulfill their promise against cancer," says Fukumura, an associate professor of Radiation Oncology at Harvard Medical School (HMS). "Our study's unveiling of a novel resistance mechanism to anti-VEGF and the molecular mechanism underlying that resistance offers a basis for the development of novel and efficient immunotherapeutic strategies to treat solid tumors."

Rakesh K. Jain, PhD, director of the Steele Labs and co-senior author of the Journal of Clinical Investigation report, adds, "Tumors also escape the immune system through immune checkpoint molecules like PD-1 and CTLA-4, which are the targets of recently approved drugs. But that strategy has been effective only in some tumor types and in only a fraction of patients. Therapeutic strategies based on our findings regarding the immunosuppressive action of non-classical monocytes may prove to have synergistic effect with those approved immune checkpoint inhibitors." Jain is the Cook Professor of Radiation Oncology (Tumor Biology) at HMS.

Explore further: Targeting two angiogenesis pathways could improve results of glioblastoma treatment

More information: Keehoon Jung et al, Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy, Journal of Clinical Investigation (2017). DOI: 10.1172/JCI93182

Related Stories

Targeting two angiogenesis pathways could improve results of glioblastoma treatment

April 4, 2016
Two companion papers from Massachusetts General Hospital (MGH) research teams suggest that targeting multiple angiogenesis pathways simultaneously could help overcome the resistance to anti-angiogenic treatment inevitably ...

Targeting blood vessels to improve cancer immunotherapy

April 12, 2017
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.

Specialized blood vessels enhance tumor-fighting immunotherapy

April 13, 2017
Scientists from VIB and KU Leuven, together with colleagues from the University of California and the Swiss Institute for Experimental Cancer Research have demonstrated that, anti-angiogenic therapy can improve immune boosting ...

Immune system molecule promotes tumor resistance to anti-angiogenic therapy

August 5, 2013
A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

Blood vessels and the immune system talk to each other; implications for cancer treatment

April 3, 2017
Some cancer therapies aim at stopping tumor growth by affecting the blood vessels that nurture the tumor mass, while others act on the immune system attempting to eliminate the tumor. Researchers at Baylor College of Medicine ...

Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment

May 24, 2017
While target therapies directed toward genetic mutations that drive a tumor's growth have significantly improved the outlook for many patients, they have not been as successful in controlling brain metastases in several types ...

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.